As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.

Discover >


Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.

Discover >

Genopole’s citizens

Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.

Discover >


Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.

Discover >

Innovate with us

Discover >

Toward the industrialization of gene therapies

The Île-de-France Administrative Region is a leader in biotechnologies and innovative biotherapies, as was demonstrated in a note recently published by Institut Paris Region with contributions from Genopole.
Laboratory Laboratory

Polytheragene is a Genopole-accredited biotech located within the Lambe laboratory at the University of Évry. The company is developing a polymer that will improve upon the current market standards for the production of viral particles for therapeutics. The polymer will be used by Genethon and Yposkesi to enhance the bioproduction of gene therapy vectors.

Polytheragene’s polymer, PTG1+, has numerous advantages over conventional transfection agents, providing a massive boost for the large-scale production of lentiviral or adeno-associated virus (AAV) gene therapy vectors.

Results obtained in a partnership between Polytheragene and Genethon have moved the latter, an AFM-Téléthon laboratory, to sign a contract with the former for the use of PTG1+ in the production of its gene therapy products for rare diseases.

Large-scale pharmaceutical-grade lots will be produced by Yposkesi, an industrial facility created by AFM-Téléthon and Bpifrance at Genopole. The productivity increase conferred by PTG1+ will also help bring production costs down and thus contribute to AFM-Téléthon’s objective of more reasonable pricing for these innovative therapies.

Hervé Cheradame, Founder, President and CEO of Polytheragene: “These results illustrate the synergies between Genopole’s actors, be they associations, public laboratories or private companies. And it’s only a start.

Polytheragene will remain the sole owner and unique developer of the polymer. The patented technology was the result of research done at the CNRS, the University of Orléans (prof. C. Pichon and Dr. P. Midoux) and the University of Évry’s Lambe laboratory (Professors H. Cheradame and P. Guegan).

Frédéric Revah, CEO of Genethon: “The technological aspects of bioproduction play key roles in ensuring patient access to innovative medicines and national independence in the domain. We are multiplying our efforts to significantly increase bioproduction yield and the Polytheragene product will enlarge our technological arsenal aimed at achieving that goal.

Alain Lamproye, CEO of Yposkesi: “Innovation is essential if we are to rise to the immense challenges encountered in gene therapy bioprocesses. The development of a suspension-compatible production platform is particularly important in this setting, as it enables an upscaling of processes and responds to commercialization needs. Polytheragene’s product is an essential component for this platform and I am pleased by the cooperation between the three entities for the development of the molecule.

The goal: industrialization of gene therapies

The number of clinical trials in gene therapies continues to grow, notably in such fields as rare immune, blood, vision or muscle diseases, and furthermore in the setting of cancer. However, more common diseases in, for example, dermatology, ophthalmology and neurodegenerative diseases have also become of interest for gene therapies.

Bioreactors producing vectors for gene therapies

The global gene therapy market is estimated at $10 billion today and that number could double by 2023. France, a pioneer in gene therapies, must defend both its place in the global market and its autonomy in the domain, to ensure access to these high-tech therapeutics and minimize its dependence on American or Swiss pharmaceutical giants.

Toward those goals, Yposkesi is France’s principle entity for the pharmaceutical production of gene therapy vectors.

Anne Jouvenceau, Acting Director General of Genopole: “The advancement of gene therapy industrialization is a major and strategic issue for Genopole. The partnership between Polytheragene and Genethon is a vivid example of what it can and should look like. Today, the presence of major entities in gene and cell therapies at Genopole places the biocluster as an essential national actor in the construction of an innovative therapies sector.



Pr Hervé Cheradame

Article posted on 26 March 2020


The latest news

I-Stem, IPSEN & LMN recreate the human muscle-nerve system

A cellular model to recreate the human muscle-nerve system

Researchers from I-Stem, IPSEN and LMN have conceived a cellular muscle-nerve model to test the therapeutic potential of botulinum toxins in vitro.

Genoscope - CNS - Genopole's laboratory

Filling the gaps in the banana’s genome

Des chercheurs de Genoscope en collaboration avec une équipe du Cirad sont parvenus à reconstituer la séquence intégrale de chromosomes de bananier.

traitement des plaies diabétiques issu de peau et d’écailles de poissons

CERITD: Treating deep wounds with fish skin

CERITD and the South Île-de-France Medical Center are testing an innovative, natural fish-skin-based treatment for diabetic foot ulcers.


Sysfate Team: A tool to digitize organs

Sysfate at Genoscope has combined image analysis and genomics to create MULTILAYER, a tool to digitize biological tissues and organs.

muscle fiber

Signs of myopathy detected before muscle formation

An I-Stem team has revealed very early embryonic molecular signs of Duchenne muscular dystrophy occurring upstream of muscle development itself

Neurons representation - Cells affected by CMT

Gene therapy for Charcot-Marie-Tooth disease makes headway

A gene therapy for Charcot-Marie-Tooth disease has been shown to be efficacious in an animal-model study cosigned by a research team created through Genopole support.

LAST - Makeup by Global Bioenergies

Global Bioenergies launches its makeup brand

Interview with Marc Delcourt, founder and CEO of Global Bioenergies, launches its makeup brand : LAST

NEB France celebrate 10 years @ Genopole

New England Biolabs France Celebrates 10 Years!

Its French affiliate arrived at Genopole in 2011 and to mark its 10th anniversary in France, the company invites you to participate in monthly activities to be held throughout 2021.

Visualization and quantification by MTBench technology of protein-protein interactions observed at Opera Phenix + in a cell line.

Seeing in high resolution at the Structural Biology Platform

With the support of Genopole & the University of Évry and to enrich its technological offer, the Structural Biology Platform has acquired the Opera Phenix Plus high content screening (HCS) system.

MSCA COFUND 2020 - ApogeeBio Laureate

COFUND-MSCA2020 : ApogeeBio chosen by the EC

Submitted by Genopole and its on-site partners, the ApogeeBio project for research grants has been selected by the European Commission for Marie Skłodowska-Curie Actions co-funding (MSCA-Cofund-2020).

Genhotel -  fibroblastes, cancer & Polyarthrite

Metabolic reprogramming involved in rheumatoid arthritis and cancer

The researchers from GenHotel (University of Évry-Paris Saclay, Genopole) have shed light on certain aspects common to rheumatoid arthritis and cancer.

AB Science L. Gros

Multiple sclerosis and COVID-19: promising results from AB Science

AB Science has been announcing a series of positive results concerning the efficacy of its product, masitinib, in such pathologies as multiple sclerosis, severe asthma resistant to oral steroids, COVID-19 and amyotrophic lateral sclerosis.

Placton - Tara Oceans

Bioinformatics and Tara Oceans

A team from the Genomics Metabolics Laboratory (Genoscope – CEA/CNRS/University of Évry) has developed a bioinformatics method for environmental genomics analyses able to identify species and associations of species.

Globules rouges - Avancées scientifiques

CRISPR-Cas9 for blood and metabolic diseases – Integrare

In an article published in Nature Communications, an Integrare team headed by Dr. Mario Amendola has described an innovative genome editing strategy aimed at modifying hematopoietic stem cells.

Généthon - Genopole's Laboratory

Treating more patients with gene therapies – Généthon

A Genethon team has successfully inhibited immune response to adeno-associated virus vectors, and in so doing, opened potential paths for treating more patients with gene therapies.

COVID-19 Disease Map

A single interactive map for all that is known on COVID-19

The objective for this latter is to build a sole referential comprising the totality of scientific knowledge on SARS-CoV-2/human-host interactions and thus contribute to the identification of therapeutic possibilities.

cellular membrane

Mapping membrane nanotubes – Lambe

A team from the Genopole-accredited Laboratory for Analysis and Modeling in Biology and the Environment (Lambe) has developed an experimental technique to study cell membrane nanotubes. These largely unknown structures play an essential role in cellular biomolecule transport.

Jean Weissenbach

Jean Weissenbach: a portrait

Jean Weissenbach, a pioneer in France for the exploration of the human genome and a scientific icon at Genopole, talks about his career in an interview published 18 March 2020 in CNRS News.

cellular membrane

A nanopore to identify amino acids – Lambe

A team from the Laboratory for Analysis and Modeling in Biology and the Environment (Lambe – University of Évry/University of Cergy-Pontoise/CNRS) used a natural aerolysin nanopore to successfully identify 13 of the 20 amino acids that make up proteins.

Genopole - European projects

Green light from Europe for the Genopole-coordinated project GEN.ERA

Le projet européen GEN.ERA*, coordonné par Genopole, est sélectionné par la Commission européenne. Il vise à renforcer par une coopération entre clusters, l’internationalisation d’entreprises du secteur de la génomique au-delà du continent européen.

View all >
With the support from